Model Innovation in Parkinson’s Disease Drug Development: Linking Quantitative Systems Pharmacology to the Patient Voice – Jeff Barrett, et al. Abstract # 287
Considerations for Participation in PPP Projects: Learnings from the Critical Path for Parkinson’s Consortium, D. Stephenson Session: # S0802-L, Understanding of Different Set Ups of PPP, Benefits of PPPs and Learnings of Recent Projects to Facilitate
C-Path’s PKDOC Presentation on Fluid-Based Biomarkers Critical Path Institute’s John-Michael Sauer, Ph.D. presents information on fluid-based biomarkers and how they can be applied
Webinar: Accelerating Drug Development for Rare Diseases through Data Sharing and Analysis (Sept.18, 2020)
How Math, Statistics, and Artificial Intelligence Can be Used to Develop Treatments for Major Diseases: Quantitative Medicine at the Critical Path Institute
